סטריפ צר

Preliminary Scientific Program

Thursday, February 21

08:00-08:30 Gathering
08:30-08:45 Greetings – Israeli Society of Hematology
The history of Myeloma
Moshe Mittleman, Chairman, Israel Society of Hematology
08:45-08:50 Greetings – Israeli Myeloma Study Group
Moshe Gatt, Chairman, Israel Myeloma Society
08:50-09:05 IMS and IMW Introduction
Jesus San Miguel, Chairman, International Myeloma Society
09:05-09:10 Opening of Congress
Merav Leiba, Secretary, Israel Myeloma Society
Session 1: Myeloma Early Disease
Moderators: Merav Leiba, Yaacov Rowe
09:10-09:40 Keynote Lecture
From bench to bedside, future targets for the treatment of MM
Kenneth Anderson
09:40-10:00 Myeloma molecular basics / Precursor Disease States
Irene Ghobriel
10:00-10:20 SMM. Is it time to treat?
Irene Ghobriel
10:20-10:40 Case presentations roundtable and local practice
Case presentation: Chezi Ganzel
Irene Ghobriel, Kenneth Anderson, Moshe Mittleman
10:40-11:00 Coffee Break
Session 2: Induction Therapy
Moderators: Noa Lavi, Adrian Duek
11:00-11:20 Induction therapy for transplant eligible
Phillipe Moreau
11:20-11:40 Induction therapy for transplant ineligible
Meletios-Athanasios Dimopoulos
Sponsored by Janssen
11:40-12:00 MRD
Jesus San Miguel
12:00-12:20 Case presentations roundtable and local practice
Case presentation: Noa Lavi
Jesus San Miguel, Meletios-Athanasios Dimopoulos, Phillipe Moreau, Tamar Tadmor
Session 3: Transplantation and Post Transplant Therapy
Moderators: Avichai Shimoni, Osnat Jarchovsky
12:20-13:00 Case presentations Transplantation Controversies – 0/1/2
Case presentation: Osnat Jarchovsky
Phillipe Moreau - YES
Paul Richardson - NO
Sponsored by Neopharm Israel
13:00-13:20 Consolidation and Maintenance therapy
Paul Richardson
Sponsored by Neopharm Israel
13:20-14:20 Lunch Break + POSTER SESSION
Session 4: Relapsed Disease
Moderators: Uri Abadi, Najib Dali
14:20-14:50 First to tenth relapse
Paul Richardson
Sponsored by Neopharm Israel
14:50-15:10 High risk disease
Merav Leiba
15:10-15:30 Primary refractory patients – The KyDaR Study
Yael Cohen
15:30-15:50 Treatment of relapsed disease outside clinical trials
Moshe Gatt
15:50-16:10 Case presentations roundtable and local practice
Case presentation: Eyal Lebel, Tamar Tadmor
Paul Richardson, Moshe Gatt, Merav Leiba, Yael Cohen, Hila Magen
16:10-16:30 Coffee Break
Session 5: Immunotherapy
Moderators: Katrin Hertzog, Ofer Shpilberg
16:30-17:10 Immunotherapy and CART
Kenneth Anderson
17:10-17:30 Case presentations roundtable and local practice
Case presentation: Adrian Duek
Kenneth Anderson, Irit Avivi
17:30-18:30 POSTER SESSION

Friday, February 22

Session 6: Myeloma Special Care
Moderators: Yossef Barshai, Julia Vaxman
08:30-08:50 Bone Disease
Evangelos Terpos
08:50-09:10 Renal care
Dr. Evangelos Terpos
09:10-09:30 Managing complications and side effects
Irit Avivi
09:30-09:50 Extra medullary disease – from solitary PC to extramedullary disease
Artur Jurczyszyn
09:50-10:10 Case presentations roundtable and local practice
Case presentation: Yossef Barshai, Julia Vaxman
Evangelos Terpos, Irit Avivi , Artur Jurczyszyn, Ori Ruvio
10:00-11:30 Nursing Forum ( Oren 1 Hall )
Detailed program below
Session 7: Myeloma Israel Perspective
Moderators: Celia Surio, Chezi Ganzel
10:10-10:40 Oral presentations of selected posters
High-dimensional immunophenotypic and signaling heterogeneity in multiple myeloma
Jana Jakubikova
Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4 enriched microvesicles.
Mahmood Dabah
Optimal Washout Period Between Bortezomib Induction and Stem Cell Mobilization in Patients with Multiple Myeloma – a Single Center Historical Prospective Analysis
Efrat Luttwak
In vitro anti-myeloma activity of CBD, THC enriched extracts and combinations thereof
Gabriela Rozic
Pre-treatment BDNF Protein Levels as Potential Biomarker for Response to Treatment and Peripheral Neuropathy development in Bortezomib-treated Multiple Myeloma Patients
Netanel Horowitz
Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience
Noa Lavi
10:40-11:00 Coffee Break
Session 8: Waldenstrom Macroglobulinemia
Moderators: Gilad Itzhaki, Pia Raanani
11:00-11:40 Waldenstrom Macroglobulinemia
Steve Treon
11:40-12:00 Case presentations roundtable and local practice
Case presentation: Gilad Itzhaki
Steve Treon, Ariel Aviv
11:30-12:20 Laboratory and Research Session ( Oren 1 Hall )
Detailed program below
Session 9: The Current and Future of MM Care
Moderators: Moshe Gatt, Merav Leiba
12:00-12:20 Critical questions for the next decade in MM- is there a cure?
Jesus San Miguel
12:20-13:00 The current and future of MM care, panel discussion and audience questions
Case presentation: Efrat Luttwak, Eyal Lebel
Phillipe Moreau, Jesus San Miguel, Dina Ben Yehuda
Sponsored by Karyopharm
13:00-13:10 Concluding remarks
13:10-14:00 Lunch

 

 

10:00-11:30 Nursing Forum - הטיפול במילומה מנקודת מבט האחות ההמטואונקולוגית
מנחה:נטלי גרקובה
10:00-10:20 גנטיקה/בדיקות מולקולריות של מיאלומה נפוצה
אדריאן דואק
10:20-11:00 Case presentation מושב מיאלומה נפוצה
מנחה:מיה בן שלמה
פאנל מומחים:
מאיה בכור
יעל פרץ
אדריאן דואק
11:00-11:30 טיפול אימונותרפי בחולים מיאלומה נפוצה
יעל כהן
11:30-12:20 Laboratory and Research Session
Moderator Michal Cipok
11:30-11:50 Towards selective targeting of the multiple myeloma-mesenchymal stem cells’ crosstalk
Liat Drucker
11:50-12:00 FROM MM TO? (CASE NO. 201033246)
Ety Shaoul
12:00-12:10 Therapeutic antibody as a pitfall for identification of endogenous monoclonal proteins –
Gabriel Bryk
12:10-12:20 Effects of Daratumumab on Pre-Transfusion Testing –
Anna Feldman